Ipamorelin

Background

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) and ghrelin receptor agonist, commonly classified among growth hormone–releasing peptides (GHRPs).[11][15] It is also referred to as GHRP‑Ipa. Ipamorelin was developed in the 1990s as part of second‑generation GHS programs aiming to improve selectivity for growth hormone (GH) release with minimal stimulation of adrenocorticotropic hormone (ACTH), cortisol, and prolactin compared with earlier GHRPs such as GHRP‑2 and GHRP‑6.[11]

Ipamorelin’s design was informed by structure–activity studies on GHRPs and small‑molecule GHS that defined a minimal bioactive pharmacophore required for ghrelin receptor activation.[14][15] It has been investigated primarily in preclinical models and early‑phase clinical studies as a potential treatment for conditions associated with GH deficiency or increased catabolic stress, including postoperative ileus and frailty, but it has not progressed to marketing authorization in the United States or European Union.[11][12]

Mechanism of action

Ipamorelin is a selective agonist of the growth hormone secretagogue receptor type 1a (GHSR1a), also known as the ghrelin receptor.[11][15] GHSR1a is a G protein‑coupled receptor expressed in the pituitary, hypothalamus, and multiple peripheral tissues including gastrointestinal tract, heart, lung, liver, kidney, pancreas, adipose tissue, and immune cells.[1][3][11]

By binding to GHSR1a in the hypothalamus and anterior pituitary, ipamorelin mimics the action of endogenous ghrelin, leading to:

• Stimulation of pulsatile GH release from somatotrophs in the anterior pituitary.[11][13]
• Subsequent increases in circulating insulin‑like growth factor‑1 (IGF‑1) via hepatic GH receptor activation.[13]

In contrast to some earlier GHRPs, ipamorelin appears relatively selective for GH with limited direct effects on ACTH and cortisol secretion at therapeutic exposure ranges.[11] At the receptor level, GHSR agonists such as ipamorelin act as orthosteric super‑agonists, with ghrelin behaving as a partial agonist in some systems.[15] In a recombinant GHSR system assessing Gαo1 activation, synthetic GHSs (including peptide and non‑peptide agonists) functioned as competitive agonists at the ghrelin orthosteric site without evidence of allosteric modulation of ghrelin efficacy, indicating classical receptor activation rather than allosteric regulation.[15]

Downstream signaling involves coupling of GHSR1a to Gq/11 and Gi/o proteins, leading to phospholipase C activation, intracellular calcium mobilization, and modulation of ion channels in hypothalamic and pituitary cells; these pathways converge to promote GH exocytosis and modulate appetite and energy homeostasis.[3][7] Although detailed, ipamorelin‑specific signaling studies are limited, its pharmacology is generally considered analogous to other peptide GHSR agonists.[11][15]

Evidence summary

Preclinical studies

Several animal and cellular studies have characterized ipamorelin’s GH‑releasing activity and peripheral endocrine effects:

• In a streptozotocin (STZ)‑induced diabetic mouse model, intravenous ipamorelin was used to interrogate GH–IGF‑1 axis responsiveness.[13] Female STZ‑diabetic and non‑diabetic mice received a single IV dose of ipamorelin or saline on day 14 of diabetes; serum GH and IGF‑1 were measured 10 minutes after injection, and hepatic GH receptor, GH‑binding protein, and IGF‑1 mRNA and peptide levels were quantified.[13] Diabetic mice exhibited GH hypersecretion and hepatic GH receptor resistance, and ipamorelin administration further increased GH but not hepatic IGF‑1 peptide, demonstrating that GHS‑induced GH release can be dissociated from IGF‑1 production in states of GH resistance.[13]

• Early structure–activity work on GHRPs and GHSs defined minimal bioactive conformations enabling potent GHSR activation in vitro and GH release in vivo, underpinning the design of later agents such as ipamorelin.[14] Rodent models in these studies demonstrated anabolic effects with intermittent GHS administration, including increased body weight and lean mass.[14]

Although ipamorelin itself is less extensively documented than other GHSs, broader ghrelin receptor biology and GHS pharmacology support its expected effects on GH secretion, appetite, and metabolism.[3][10][11][12]

Human data

Ipamorelin has limited published human clinical data. It is frequently mentioned alongside other GHSs (sermorelin, GHRP‑2, GHRP‑6, ibutamoren) in reviews of growth hormone secretagogues for body composition and hypogonadism, but with scarce agent‑specific outcome data.

• A narrative review on growth hormone secretagogues in hypogonadal males discusses ipamorelin as a potent stimulant of GH and IGF‑1 that may improve body composition when used adjunctively, but emphasizes that human evidence is limited and largely extrapolated from data on other GHSs such as ibutamoren.[12] Controlled trials with ipamorelin in this population are not detailed.

• Brief reference summaries describe ipamorelin as a selective GH‑releasing agent with reduced impact on other pituitary hormones and with pharmacodynamic GH responses similar to those seen with growth hormone–releasing hormone (GHRH) analogs.[11] Quantitative details on sample size, dose–response relationships, and clinical endpoints are not provided in these secondary summaries.

Published trial‑level data (e.g., phase 1 or 2 dose‑escalation studies) appear limited or not readily accessible in the mainstream clinical trial registry and journal literature, indicating an overall sparse and fragmentary human evidence base as of the most recent searches.

Clinical and research uses

Investigational and off‑label contexts

Given its pharmacology, ipamorelin has been explored or proposed for several indications:

• GH deficiency and age‑related decline in GH/IGF‑1: Reviews and expert commentary position ipamorelin among GHSs that could potentially augment endogenous GH secretion in adults with low GH output or age‑related changes in body composition.[11][12] However, clinical data consist mainly of early‑phase pharmacodynamic observations and extrapolation from other GHSs.

• Body composition and hypogonadism: In the context of male hypogonadism, GHSs are discussed as potential adjuncts to optimize lean mass and fat mass, though the most robust human data relate to ibutamoren; for ipamorelin, evidence is limited and no large, randomized ipamorelin‑specific trials are cited.[12]

• Catabolic states and critical illness: By analogy with other GHSs, ipamorelin has been considered for conditions characterized by muscle wasting or catabolic stress, but peer‑reviewed ipamorelin‑specific outcome studies in these settings are sparse.[12]

At present, ipamorelin is mainly a research tool and investigational agent rather than an established therapeutic in mainstream medicine.

Non‑medical and gray‑market use

Reviews on body composition note that peptide GHSs, including ipamorelin, are widely discussed in non‑regulated settings (e.g., sports and “anti‑aging” communities), but such uses are off‑label, unapproved, and poorly characterized by systematic clinical research.[12]

Dosing context

No ipamorelin dose has regulatory approval, and dosing information is derived from preclinical studies and limited human pharmacology reports rather than formal label guidance.

• In mice, ipamorelin has been administered intravenously in single doses (exact mg/kg values vary by protocol) to acutely stimulate GH release and probe GH–IGF‑1 axis function.[13]

• Secondary summaries describe ipamorelin as being studied via parenteral administration (typically subcutaneous or intravenous) with short‑acting GH pulses analogous to those seen with other peptide GHSs and GHRH analogs.[11]

Because detailed human dose‑finding data (e.g., specific microgram/kg ranges, dose–response curves, and maximum tolerated doses) are not consistently reported in accessible literature, ipamorelin dosing should be regarded as insufficiently characterized for clinical use.

Safety profile

Published data specific to ipamorelin’s safety profile are limited. Safety expectations are largely extrapolated from its mechanism and from the broader GHS class.

Adverse effects (expected and reported)

Based on GHS experience:

• GH/IGF‑1–related effects: Chronic GH elevation can be associated with fluid retention, edema, arthralgia, carpal tunnel syndrome, glucose intolerance, and potential promotion of neoplastic growth, although these risks are dose‑ and duration‑dependent and data specific to ipamorelin are limited.[12]

• Pituitary–adrenal axis: Ipamorelin was designed to minimize ACTH and cortisol stimulation relative to earlier GHRPs, suggesting a reduced risk of cortisol‑related adverse effects; nonetheless, detailed comparative endocrine safety data remain limited to small pharmacology datasets.[11]

• Metabolic effects: GHSR activation modulates appetite and glucose homeostasis.[3][10][12] Ghrelin pathway stimulation can increase food intake and body weight and may worsen glucose tolerance in some settings; these effects are mechanistically plausible with ipamorelin but require more robust human data.

• Injection‑related reactions: As a parenteral peptide, local injection‑site reactions are possible but not well documented in the literature.

Contraindications and cautions (theoretical)

Because ipamorelin enhances GH secretion, potential risk groups—based on GH biology and GHS class effects rather than ipamorelin‑specific trials—include:

• Individuals with active malignancy or a history of cancer at risk of GH/IGF‑1–driven tumor growth.
• Patients with diabetic retinopathy or uncontrolled diabetes, given the interplay between GH, IGF‑1, and microvascular complications.
• Patients with intracranial hypertension or pre‑existing pituitary adenomas, where increased GH and pituitary stimulation may pose risks.

In the STZ‑diabetic mouse model, ipamorelin accentuated GH hypersecretion without restoring IGF‑1, highlighting that in states of GH resistance the peptide can further perturb endocrine balance without clear anabolic benefit.[13]

Overall, ipamorelin’s long‑term safety in humans remains poorly defined, and high‑quality clinical safety data are lacking.

Regulatory status

As of the most recent evidence review, ipamorelin does not have marketing authorization as a medicinal product in the United States or the European Union. It is not listed among FDA‑approved GH‑modulating agents, and there is no EMA public assessment report or centralized authorization for ipamorelin.

In contrast, the non‑peptide GHS ibutamoren (MK‑0677) has been the subject of more extensive development and is recognized in the context of doping control, but it likewise lacks formal approval for therapeutic use.[8][9][12]

Ipamorelin is therefore best characterized as an experimental ghrelin receptor agonist with limited clinical data and no current formal regulatory approval in major jurisdictions. Its use in clinical practice would be considered investigational or off‑label where permitted by local regulations, and any such use should be restricted to well‑designed clinical trials with appropriate oversight.